Insider Trading activities of Alder Biopharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alder Biopharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Alder Biopharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Alder Biopharmaceuticals Inc since 2005. The reporting company's ticker symbol is ALDR. The reporting company's CIK number is 1423824.
The total value of stock buying since 2005 is $17,830,000.
The total value of stock sales since 2005 is $100,776,093.
The total value of stock option exercises since 2005 is $777,544.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Alder Biopharmaceuticals Inc (ALDR).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-10 0 $0 16,520 $203,708 16,520 $27,258
2017-07 30,000 $300,000 0 $0 0 $0
2017-06 0 $0 585 $11,700 585 $579
2017-02 0 $0 30,000 $750,750 30,000 $49,500
2017-01 0 $0 11,014 $253,593 11,014 $16,013
2016-12 0 $0 19,908 $460,326 19,908 $32,847
2016-11 0 $0 23,000 $627,157 23,000 $37,950
2016-10 0 $0 27,181 $827,076 21,181 $31,798
2016-09 0 $0 23,000 $748,131 23,000 $34,099
2016-08 0 $0 23,000 $727,493 23,000 $34,099
2016-07 0 $0 20,000 $582,226 45,000 $38,773
2016-06 0 $0 42,090 $1,271,288 36,090 $49,502
2016-05 0 $0 75,000 $2,233,051 75,000 $79,357
2016-04 0 $0 30,000 $841,961 30,000 $21,691
2016-01 0 $0 45,000 $1,420,185 45,000 $26,124
2015-12 0 $0 18,822 $700,983 18,822 $7,245
2015-11 0 $0 18,533 $622,010 18,445 $7,100
2015-10 0 $0 15,945 $518,687 8,445 $3,250
2015-09 0 $0 8,445 $326,185 78,008 $125,088
2015-08 0 $0 678,282 $27,286,790 8,445 $3,250
2015-07 0 $0 15,945 $815,218 8,445 $3,250
2015-06 0 $0 83,899 $3,770,147 83,899 $64,499
2015-05 0 $0 1,334,544 $50,154,499 158,444 $64,898
2015-04 0 $0 15,945 $437,158 8,445 $3,250
2015-03 0 $0 22,945 $659,611 22,945 $8,832
2015-01 0 $0 126,445 $3,589,281 18,945 $7,292
2014-11 0 $0 59,090 $936,879 0 $0
2014-05 1,753,000 $17,530,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Alder Biopharmaceuticals Inc insiders (ALDR)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-10-16 Litton Mark James (Chief Business Officer) Sale 16,520 12.33 203,708
2017-10-16 Litton Mark James (Chief Business Officer) Option Ex 16,520 1.65 27,258
2017-07-18 Yarno Wendy L (Director) Buy 5,000 10.00 50,000
2017-07-18 Dow Stephen M (Director) Buy 25,000 10.00 250,000
2017-06-20 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 585 20.00 11,700
2017-06-20 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 585 .99 579
2017-02-09 Schatzman Randall C (President and CEO) Sale 30,000 25.02 750,750
2017-02-09 Schatzman Randall C (President and CEO) Option Ex 30,000 1.65 49,500
2017-01-18 Litton Mark James (Chief Business Officer) Sale 1,498 23.10 34,599
2017-01-18 Litton Mark James (Chief Business Officer) Option Ex 1,498 1.65 2,471
2017-01-09 Litton Mark James (Chief Business Officer) Sale 500 23.00 11,500
2017-01-09 Litton Mark James (Chief Business Officer) Option Ex 500 1.65 825
2017-01-06 Litton Mark James (Chief Business Officer) Sale 6,800 23.02 156,522
2017-01-06 Litton Mark James (Chief Business Officer) Option Ex 6,800 1.46 9,914
2017-01-05 Litton Mark James (Chief Business Officer) Sale 2,216 23.00 50,972
2017-01-05 Litton Mark James (Chief Business Officer) Option Ex 2,216 1.26 2,803
2016-12-01 Latham John A (Chief Scientific Officer) Sale 7,272 23.13 168,200
2016-12-01 Latham John A (Chief Scientific Officer) Option Ex 7,272 1.65 11,998
2016-12-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 6,000 23.11 138,684
2016-12-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 6,000 1.65 9,900
2016-11-09 Latham John A (Chief Scientific Officer) Sale 10,000 30.18 301,840
2016-11-09 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.65 16,500
2016-11-07 Schatzman Randall C (President and CEO) Sale 10,000 25.16 251,610
2016-11-07 Schatzman Randall C (President and CEO) Option Ex 10,000 1.65 16,500
2016-11-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,000 24.57 73,707
2016-11-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,000 1.65 4,950
2016-10-17 Litton Mark James (Chief Business Officer) Sale 6,000 27.50 165,000
2016-10-03 Latham John A (Chief Scientific Officer) Sale 10,000 31.25 312,510
2016-10-03 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.65 16,500
2016-10-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,000 31.31 93,918
2016-10-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,000 1.65 4,950
2016-10-03 Schatzman Randall C (President and CEO) Sale 8,181 31.25 255,648
2016-10-03 Schatzman Randall C (President and CEO) Option Ex 8,181 1.26 10,348
2016-09-01 Latham John A (Chief Scientific Officer) Sale 10,000 32.49 324,950
2016-09-01 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.65 16,500
2016-09-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,000 32.79 98,361
2016-09-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,000 1.65 4,950
2016-09-01 Schatzman Randall C (President and CEO) Sale 10,000 32.48 324,820
2016-09-01 Schatzman Randall C (President and CEO) Option Ex 10,000 1.26 12,649
2016-08-15 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,000 31.17 93,513
2016-08-15 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,000 1.65 4,950
2016-08-01 Latham John A (Chief Scientific Officer) Sale 10,000 31.72 317,230
2016-08-01 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.65 16,500
2016-08-01 Schatzman Randall C (President and CEO) Sale 10,000 31.68 316,750
2016-08-01 Schatzman Randall C (President and CEO) Option Ex 10,000 1.26 12,649
2016-07-27 Latham John A (Chief Scientific Officer) Sale 9,187 30.15 277,024
2016-07-27 Latham John A (Chief Scientific Officer) Option Ex 9,187 1.65 15,158
2016-07-26 Latham John A (Chief Scientific Officer) Sale 813 30.00 24,392
2016-07-26 Latham John A (Chief Scientific Officer) Option Ex 813 1.65 1,341
2016-07-25 Schatzman Randall C (President and CEO) Sale 10,000 28.08 280,810
2016-07-25 Schatzman Randall C (President and CEO) Option Ex 10,000 1.26 12,649
2016-07-12 Litton Mark James (Chief Business Officer) Option Ex 25,000 .39 9,625
2016-06-13 Litton Mark James (Chief Business Officer) Sale 6,000 29.25 175,524
2016-06-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 16,090 30.87 496,714
2016-06-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 16,090 1.26 20,353
2016-06-01 Latham John A (Chief Scientific Officer) Sale 10,000 30.02 300,220
2016-06-01 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.65 16,500
2016-06-01 Schatzman Randall C (President and CEO) Sale 10,000 29.88 298,830
2016-06-01 Schatzman Randall C (President and CEO) Option Ex 10,000 1.26 12,649
2016-05-31 Latham John A (Chief Scientific Officer) Sale 33,599 30.04 1,009,280
2016-05-31 Latham John A (Chief Scientific Officer) Option Ex 33,599 1.46 48,987
2016-05-31 Litton Mark James (Chief Business Officer) Sale 19,720 30.05 592,566
2016-05-31 Litton Mark James (Chief Business Officer) Option Ex 19,720 .39 7,592
2016-05-27 Latham John A (Chief Scientific Officer) Sale 6,401 30.05 192,337
2016-05-27 Latham John A (Chief Scientific Officer) Option Ex 6,401 1.26 8,097
2016-05-27 Litton Mark James (Chief Business Officer) Sale 5,280 30.06 158,695
2016-05-27 Litton Mark James (Chief Business Officer) Option Ex 5,280 .39 2,032
2016-05-24 Schatzman Randall C (President and CEO) Sale 4,017 28.03 112,588
2016-05-24 Schatzman Randall C (President and CEO) Option Ex 4,017 1.26 5,081
2016-05-23 Schatzman Randall C (President and CEO) Sale 2,997 28.01 83,951
2016-05-23 Schatzman Randall C (President and CEO) Option Ex 2,997 1.26 3,791
2016-05-20 Schatzman Randall C (President and CEO) Sale 2,986 28.01 83,634
2016-05-20 Schatzman Randall C (President and CEO) Option Ex 2,986 1.26 3,777
2016-04-18 Schatzman Randall C (President and CEO) Sale 4,514 28.08 126,744
2016-04-18 Schatzman Randall C (President and CEO) Option Ex 4,514 1.26 5,710
2016-04-15 Schatzman Randall C (President and CEO) Sale 14,024 28.11 394,144
2016-04-15 Schatzman Randall C (President and CEO) Option Ex 14,024 .82 11,569
2016-04-14 Schatzman Randall C (President and CEO) Sale 11,462 28.01 321,073
2016-04-14 Schatzman Randall C (President and CEO) Option Ex 11,462 .39 4,412
2016-01-04 Latham John A (Chief Scientific Officer) Sale 10,000 31.55 315,520
2016-01-04 Latham John A (Chief Scientific Officer) Option Ex 10,000 1.26 12,649
2016-01-04 Litton Mark James (Chief Business Officer) Sale 25,000 31.52 788,125
2016-01-04 Litton Mark James (Chief Business Officer) Option Ex 25,000 .39 9,625
2016-01-04 Schatzman Randall C (President and CEO) Sale 10,000 31.65 316,540
2016-01-04 Schatzman Randall C (President and CEO) Option Ex 10,000 .39 3,850
2015-12-01 Latham John A (Chief Scientific Officer) Sale 4,550 37.24 169,451
2015-12-01 Latham John A (Chief Scientific Officer) Option Ex 4,550 .39 1,751
2015-12-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 4,272 37.24 159,102
2015-12-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 4,272 .39 1,644
2015-12-01 Schatzman Randall C (President and CEO) Sale 10,000 37.24 372,430
2015-12-01 Schatzman Randall C (President and CEO) Option Ex 10,000 .39 3,850
2015-11-30 Dow Stephen M Sale 88 37.11 3,265
2015-11-02 Latham John A (Chief Scientific Officer) Sale 4,545 33.48 152,148
2015-11-02 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-11-02 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 33.71 131,457
2015-11-02 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-11-02 Schatzman Randall C (President and CEO) Sale 10,000 33.51 335,140
2015-11-02 Schatzman Randall C (President and CEO) Option Ex 10,000 .39 3,850
2015-10-01 Latham John A (Chief Scientific Officer) Sale 4,545 32.55 147,939
2015-10-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-10-01 Litton Mark James (Chief Business Officer) Sale 7,500 32.52 243,870
2015-10-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 32.53 126,878
2015-10-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-09-24 Latham John A (Chief Scientific Officer) Option Ex 31,818 .99 31,499
2015-09-24 Litton Mark James (Chief Business Officer) Option Ex 12,764 1.26 16,146
2015-09-24 Benedict Larry (Sr. VP Finance) Option Ex 24,981 2.97 74,193
2015-09-01 Latham John A (Chief Scientific Officer) Sale 4,545 38.68 175,786
2015-09-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-09-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 38.56 150,399
2015-09-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-08-31 Sevin Rosen Ix Affiliates Fund L.p. Sale 16,218 38.75 628,463
2015-08-31 Dow Stephen M Sale 16,218 38.75 628,463
2015-08-12 Sevin Rosen Ix Affiliates Fund L.p. Sale 97,109 40.03 3,887,370
2015-08-12 Sturiale Nicholas G Sale 97,109 40.03 3,887,370
2015-08-12 Dow Stephen M Sale 97,109 40.03 3,887,370
2015-08-11 Sevin Rosen Ix Affiliates Fund L.p. Sale 115,358 40.40 4,660,809
2015-08-11 Sturiale Nicholas G Sale 115,358 40.40 4,660,809
2015-08-11 Dow Stephen M Sale 115,358 40.40 4,660,809
2015-08-03 Latham John A (Chief Scientific Officer) Sale 4,545 45.62 207,324
2015-08-03 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-08-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 45.64 178,003
2015-08-03 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-07-01 Latham John A (Chief Scientific Officer) Sale 4,545 51.13 232,381
2015-07-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-07-01 Litton Mark James (Chief Business Officer) Sale 7,500 51.10 383,220
2015-07-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 51.18 199,617
2015-07-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-06-12 Benedict Larry (Sr. VP Finance) Sale 25,454 47.46 1,208,097
2015-06-12 Benedict Larry (Sr. VP Finance) Option Ex 25,454 1.65 41,999
2015-06-04 Latham John A (Chief Scientific Officer) Sale 25,000 44.18 1,104,475
2015-06-04 Latham John A (Chief Scientific Officer) Option Ex 25,000 .39 9,625
2015-06-04 Litton Mark James (Chief Business Officer) Sale 25,000 44.27 1,106,850
2015-06-04 Litton Mark James (Chief Business Officer) Option Ex 25,000 .39 9,625
2015-06-01 Latham John A (Chief Scientific Officer) Sale 4,545 41.53 188,758
2015-06-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-06-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 41.53 161,967
2015-06-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-05-26 Schatzman Randall C (President and CEO) Sale 50,000 38.96 1,948,100
2015-05-26 Schatzman Randall C (President and CEO) Option Ex 50,000 .39 19,250
2015-05-22 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 7,202 38.47 277,024
2015-05-22 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 7,202 .06 396
2015-05-21 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 54,616 38.92 2,125,490
2015-05-21 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 54,616 .06 3,003
2015-05-21 Dow Stephen M Sale 20,000 65.69 1,313,839
2015-05-19 Sevin Rosen Ix Affiliates Fund L.p. Sale 1,136,100 37.02 42,059,558
2015-05-19 Benedict Larry (Sr. VP Finance) Sale 20,000 38.86 777,200
2015-05-19 Benedict Larry (Sr. VP Finance) Option Ex 20,000 1.65 33,000
2015-05-18 Siegall Clay B (Director) Sale 20,000 39.97 799,419
2015-05-14 Siegall Clay B (Director) Sale 18,181 35.04 637,080
2015-05-14 Siegall Clay B (Director) Option Ex 18,181 .33 5,999
2015-05-01 Latham John A (Chief Scientific Officer) Sale 4,545 25.67 116,661
2015-05-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-05-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 25.67 100,128
2015-05-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-04-01 Latham John A (Chief Scientific Officer) Sale 4,545 27.42 124,610
2015-04-01 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-04-01 Litton Mark James (Chief Business Officer) Sale 7,500 27.41 205,552
2015-04-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 27.43 106,996
2015-04-01 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-03-30 Latham John A (Chief Scientific Officer) Sale 14,500 30.20 437,914
2015-03-30 Latham John A (Chief Scientific Officer) Option Ex 14,500 .39 5,582
2015-03-02 Latham John A (Chief Scientific Officer) Sale 4,545 26.26 119,342
2015-03-02 Latham John A (Chief Scientific Officer) Option Ex 4,545 .39 1,749
2015-03-02 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 3,900 26.25 102,355
2015-03-02 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 3,900 .39 1,501
2015-01-27 Latham John A (Chief Scientific Officer) Sale 7,145 28.73 205,275
2015-01-27 Latham John A (Chief Scientific Officer) Option Ex 7,145 .39 2,750
2015-01-27 Litton Mark James (Chief Business Officer) Sale 2,300 28.52 65,602
2015-01-27 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 1,200 28.27 33,921
2015-01-27 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 1,200 .39 462
2015-01-27 Schatzman Randall C (President and CEO) Sale 63,578 28.71 1,825,197
2015-01-26 Latham John A (Chief Scientific Officer) Sale 7,900 27.98 221,010
2015-01-26 Latham John A (Chief Scientific Officer) Option Ex 7,900 .39 3,041
2015-01-26 Litton Mark James (Chief Business Officer) Sale 5,200 28.02 145,730
2015-01-26 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 2,700 27.89 75,316
2015-01-26 Smith Jeffrey T L (Sr. VP Translational Medicine) Option Ex 2,700 .39 1,039
2015-01-26 Schatzman Randall C (President and CEO) Sale 36,422 27.93 1,017,230
2014-11-24 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 9,090 16.91 153,739
2014-11-21 Smith Jeffrey T L (Sr. VP Translational Medicine) Sale 20,000 15.71 314,120
2014-11-20 Litton Mark James (Chief Business Officer) Sale 30,000 15.63 469,020
2014-05-13 Bridger Gary (Director) Buy 250,000 10.00 2,500,000
2014-05-13 Ventures West 8 Limited Partnership (10% Owner) Buy 250,000 10.00 2,500,000
2014-05-13 Novo A/s (Other) Buy 550,000 10.00 5,500,000
2014-05-13 Montgomery Alan Bruce (Director) Buy 3,000 10.00 30,000
2014-05-13 Pakianathan Deepika (Director) Buy 350,000 10.00 3,500,000
2014-05-13 Bochnowski James J (10% Owner) Buy 350,000 10.00 3,500,000

Insider trading activities including stock purchases, stock sales, and option exercises of ALDR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Alder Biopharmaceuticals Inc (symbol ALDR, CIK number 1423824) see the Securities and Exchange Commission (SEC) website.